Genprex is harnessing the power of a combinational treatment approach to overcome treatment limitations and offer patients new treatment options.
Austin-based biotech firm Genprex is looking for more growth after raising about $25.5 million through two recent stock offerings.
The Company intends to use the net proceeds from the offering to advance its drug development programs and for working capital and general corporate purposes.
The closing of the registered direct offering is expected to take place on or about February 21, 2020, subject to the satisfaction of customary closing conditions.
Technology Networks spoke with Rodney Varner, CEO of Genprex, to learn more about the next steps for Oncoprex and how the FDA Fast Track Designation will facilitate the delivery of this drug to cancer patients.
Thirty million Americans are living with diabetes and hoping someday to be cured. That day could come sooner than expected, thanks to a team of researchers at UPMC Children’s Hospital of Pittsburgh. original article: UPMC Children’s Hospital Researchers Working On ‘Groundbreaking’ Procedure To Cure Diabetes – CBS Pittsburgh (cbsnews.com)
Genprex signed an exclusive license agreement with the University of Pittsburgh for a diabetes gene therapy that may have the potential to cure Type 1 and Type 2 diabetes, which together currently affect approximately 30.3 million people in the U.S, or 9 percent of the U.S. population.
Genprex said that after receiving the US Food and Drug Administration's fast track designation last month for its immunogene therapy Oncoprex in combination with the EGFR tyrosine kinase inhibitor (TKI) osimertinib (AstraZeneca’s Tagrisso), the clinical-stage gene therapy company is prioritizing development of this therapy combination for EGFR-mutated non-small cell lung cancer.
Genprex announced that it received notice from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule.
Genprex provides a clinical update and focus for its Oncoprex™ immunogene therapy program for 2020, prioritizing the development of Oncoprex in combination with osimertinib for the treatment of non-small cell lung cancer (NSCLC).
Designed and Secured by Barsec